Marketing Approval Application Submitted to MHLW for NPC-17 (titanium bridge) -- MEDICA Trade Fair

07/07/2017

Nobelpharma Co., Ltd.

Marketing Approval Application Submitted to MHLW for NPC-17 (titanium bridge)

Nobelpharma Co., Ltd. (Chuo-ku, Tokyo) has submitted its application for marketing approval for NPC-17 (titanium bridge) to the Ministry of Health, Labour and Welfare on June 30.
NPC-17 (hereafter “this product”) is used for type II thyroplasty for the treatment of adductor spasmodic dysphonia. Type II thyroplasty using this product is a medical technique unique to Japan that was developed in 2001 ahead of the rest of the world by Dr. Nobuhiko Isshiki, Professor Emeritus, Kyoto University, as a definitive treatment for the symptoms of adductor spasmodic dysphonia.
This product was the first medical device to receive the SAKIGAKE designation from the Ministry of
Health, Labour and Welfare in February of last year, upon fulfilling the criteria for innovativeness, the
importance of the target disease, extremely high efficacy for the target disease, and the intent for early
development and application in Japan ahead of the rest of the world.

Exhibitor Data Sheet